To identify subtypes of CRC that might benefit from targeting p130Cas survival, analyses were extended to different subgroups in the TCGA CoAd data set based on localization, stage, consensus molecular subtype (CMS), as well as MSI and BRAF/KRAS status (Figure 6). This evidence concerns the gene KRAS and colorectal carcinoma.